Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Somatostatin receptor agonist polypeptide and its application

A somatostatin receptor and agonist technology, which is applied in the field of somatostatin receptor agonist polypeptides, can solve problems such as the development of somatostatin receptor agonist polypeptide liver cancer drugs, and achieve the prevention and treatment of liver cancer recurrence , Promote activity, improve the effect of survival rate

Inactive Publication Date: 2016-06-08
ZHOUSHAN HOSPITAL
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no well-developed somatostatin receptor agonist polypeptide drug for the treatment of liver cancer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Somatostatin receptor agonist polypeptide and its application
  • Somatostatin receptor agonist polypeptide and its application
  • Somatostatin receptor agonist polypeptide and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0014] Effect of Somatostatin Receptor Agonist Peptides on the Affinity of Somatostatin Receptor and Somatostatin in Vitro.

[0015] HepG2 cells grown logarithmically at 1.0 x 10 5 Add it into a 96-well culture plate, cultivate for 24 hours, add different concentrations of the experimental drug somatostatin receptor agonist polypeptide 2 and the positive control drug vincristine in the experimental wells and positive drug control wells; add the same volume of solvent to the blank group, and simultaneously ,join in 125 I-labeled somatostatin. Five replicate wells were set up in each well, and cultured for 48 hours. Wash away the supernatant, calculate the radiation intensity with a γ-liquid scintillation counter, and judge the binding force between the somatostatin receptor and somatostatin. The stronger the radiation intensity, the more the binding. Conversely, the weaker the radiation intensity, the more binding. few. The results showed that as the concentration of somato...

Embodiment 2

[0020] IC50 of somatostatin receptor agonist polypeptide 2 on the growth and survival of tumor cells cultured in vitro.

[0021] The MTT colorimetric method was used. HepG2 cells with logarithmic growth were added to 96-well culture plate at 1.0×105 and cultured for 24 hours. Different concentrations of experimental drug somatostatin receptor agonist polypeptide 2 and positive control drug Changchun Neobase; add the same volume of solvent to the blank group. Set up five duplicate wells per well, culture for 48h, add MTT to each well at 0h, 2h, 8h, 14h, 20h, 24h, 36h, and 48h respectively, add DMSO after 4h of action, incubate for 30min, and incubate at 620nm in a microplate reader Measure the absorbance A value, according to the formula tumor cell growth inhibition rate=(1-absorbance value of the experimental group / absorbance value of the control group)×100%. The calculated IC50 of the experimental drug was 7.49 μM.

Embodiment 3

[0023] Effect of Somatostatin Receptor Agonist Peptides on HepG2 Cell Migration.

[0024] 10 mg / ml Matrigel (BD Company, USA) was diluted 1:3 with serum-free cell culture medium, coated on a Transwell chamber (Greiner Company, USA) membrane, and air-dried at room temperature. HepG2 cells cultured to the logarithmic growth phase were digested with trypsin, collected, resuspended in serum-free cell culture medium, counted under a microscope, and the cell concentration was adjusted to 1×105 cells / ml. Prepare each group of test liquids, and group them as follows: Blank control group: serum-free cell culture fluid without drugs; Endostar group: dilute 5 mg / ml of Endostar stock solution to Predetermined concentration; somatostatin receptor agonist polypeptide group: the somatostatin receptor agonist polypeptide is diluted to each predetermined concentration with drug-free serum-free cell culture medium. The cells were inoculated into the Transwell chamber, 100 μl per well, and each...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of medicine, in particular to a polypeptide capable of inhibiting the expression of somatostatin and treating liver cancer. Its sequence is GGLGLPFLATQNAAS, which is a brand-new sequence, which promotes the binding of somatostatin in vitro, and improves the survival rate of tumor-bearing mice in vivo, and has potential new drug development value.

Description

technical field [0001] The invention relates to a somatostatin receptor agonist polypeptide and its application, in particular to a polypeptide capable of promoting somatostatin receptor activity and treating liver cancer. Background technique [0002] Liver cancer is one of the most common malignant tumors in my country. Since the 1990s, the mortality rate of liver cancer in my country has risen to the second place among malignant tumors, and about 130,000 people die of liver cancer every year. Primary liver cancer develops rapidly. Without treatment, the average natural survival period is 4.3 months. Even with surgical resection, the prognosis is not ideal. The 5-year survival rate is 37.2%, and the 5-year survival rate after surgery for small liver cancer is only 53.5%. %. Recurrence and metastasis are the main reasons affecting the effect of surgical treatment for patients with liver cancer. The postoperative recurrence rate of liver cancer can be as high as 60%, even ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K7/08A61K38/10A61P35/00
Inventor 马海洁张国强彭敏霞胡晓斐吴丽萍竺王玉
Owner ZHOUSHAN HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com